Lords Mark IndustriesQ1 FY27

Lords Mark Industries Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹77.45P/E: 38.9Market Cap: ₹3.3K CrSector: Commercial Services & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 2
  • FY27 revenue projected at around ₹1,550 crores with ~20.8% EBITDA margin and ~12.8% PAT margin.
  • FY28 expected consolidated revenue to cross ₹2,100 crores, representing over 25% growth from FY27.
  • EBITDA margin for FY28 expected to expand to around 23-24%.
  • Dialysis machine production capacity to increase from ~60 machines/month currently to 150 machines/month by end of next year.
  • Commercial adoption of dialysis machines growing with confirmed order book of 500+ machines.
  • Sickle cell testing expected to contribute significantly to FY28 revenues post-approval and tender.
  • New medtech products at commercialization stage anticipated to add revenue from Q4 FY27 onwards.
  • Expansion of dialysis centers and 27 cancer centers over 5-7 years to support recurring revenues.
  • Strong growth in MedTech expected to outpace renewable energy business revenue, with MedTech contributing over 50% revenue share in coming years.

See what Lords Mark Industries management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
- The company plans to reduce promoter equity to 75% to meet SEBI's Minimum Public Shareholding (MPS) requirement. - Broadly, around 4%-5% promoter equity is planned to be diluted. - Approximately 3% equity will be diluted via an Offer for Sale (OFS) with promoters infusing the money back into the company. - The remaining 2% dilution is planned through preference shares or equity. - No specific mention of new debt fundraising in the transcript. - Capex of around ₹300 crore is planned over the next 2-3 years for setting up manufacturing and R&D facilities, funded presumably through internal accruals or existing resources. - Management expects positive operating cash flow by FY27 end or by Q2 FY28, indicating no immediate need for external fundraising. Thus, equity dilution for regulatory compliance is planned; no explicit new fundraising through debt or fresh equity announced.

See what Lords Mark Industries management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company plans a capex of around ₹300-350 crores over the next 2-3 years.
  • Investment includes setting up a new manufacturing plant for dialysis machines and other upcoming MedTech products.
  • A 2-acre site in Lucknow has been acquired to establish India’s/Asia’s largest IVD and biochemistry analyzer manufacturing facility.
  • The dialysis manufacturing is currently partly outsourced; the new plant aims to bring production in-house to reduce dependency on OEMs.
  • R&D investments target oncology, TB detection, dialysis, genomics, sickle cell screening, and AI integration across devices.
  • Strategic focus on partnerships, global expansion (subsidiaries in the UK, Switzerland), and pipeline approvals.
  • Plans to expand dialysis centers (50 centers planned) with partners contributing infrastructure investments.
  • A strategic option under consideration includes separating renewable business to focus independently on MedTech growth.

Track Lords Mark Industries — get its next earnings analysis in your feed

How does Lords Mark Industries rank vs peers in Commercial Services & Supplies?

Pro feature
ThisLords Mark Industries
Rev 2Mar 1

How does Lords Mark Industries rank in Commercial Services & Supplies?

Compare Lords Mark Industries against every Commercial Services & Supplies company (Q1 FY27) on revenue, margins and earnings-call signals.

View Commercial Services & Supplies leaderboard →

What Lords Mark Industries's management said in earlier quarters

Others in Commercial Services & Supplies this season

  • Cadsys (India) (Q2 FY27)

    Consolidated revenue for H1 FY 2026-27 was ₹39.85 crore, compared to ₹69.98 crore in H1 FY 2025-26, indicating a year-on-year decline in revenue. Key investor p

  • IIRM Holdings (Q2 FY27)

    Revenue from Operations for Q2 FY27: ₹672.5 million (Page 15) . Key investor presentation takeaways from IIRM Holdings India Ltd's Q2 FY27 investor presentation

  • Manglam Infra (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026 is ₹1,019.03 lakhs, compared to ₹1,300.69 lakhs for the half year ended September 30, 2025…

  • Armour Security (Q2 FY27)

    210.96 Lakhs (~10.7%) (Page 6). Key results statement takeaways from Armour Security (India) Ltd's Q2 FY27 results statement — and how it ranks against sector p

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →